Background—Trial data for the benefits and risks of dabigatran versus warfarin in the
treatment of nonvalvular atrial fibrillation are lacking. We sought to review real-world …

Background The recent availability of dabigatran, a novel oral anticoagulant, provided a new
treatment option for stroke prevention in atrial fibrillation beyond warfarin, the main therapy …

The RE-LY study demonstrated the safety and efficacy of dabigatran relative to warfarin for
stroke prevention in non-valvular atrial fibrillation. It is important to further evaluate safety …

Objectives: The aim of this study was to assess the efficacy and safety in an “everyday
clinical practice” population of anticoagulant-naïve patients with atrial fibrillation (AF) treated …

In the RE-LY clinical trial, dabigatran presented a better effectiveness/safety profile when
compared to warfarin. However, clinical trials are not very representative of the real-world …

Dabigatran is approved for stroke risk reduction in patients with nonvalvular atrial fibrillation
(NVAF). Data from diverse clinical practice settings will help establish whether the risk …

Objective The prevalence of atrial fibrillation (AF) and the risk of stroke and bleeding vary
according to age. To estimate effects of dabigatran, compared with warfarin, on stroke …

Background Dabigatran, an oral direct thrombin inhibitor, possesses several advantages
over warfarin that can in principle simplify the management of stroke prevention in atrial …

Background Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases
the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin …

Background and Purpose—Whether dabigatran is associated with different risks of
cardiovascular, bleeding events, and mortality from warfarin in Asian patients with …